Clin2
NCT06678113Possibly a fitRecruiting

Testing a new IV drug for serious fungal infections

Invasive Fungal Infection

Part of Infections clinical trials.

This trial tests BSG005, a new IV medicine for patients with invasive fungal infections that haven't improved with standard treatment or can't use standard treatments due to side effects or resistance. The goal is to see if it's safe and effective.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
15 people
Ages
18 years to 100 years
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have a proven or probable invasive fungal infection (like from Aspergillus or Candida)
  • Your current treatment either isn't working, caused kidney or electrolyte problems, or interacts badly with other meds
  • Your kidney function is not severely reduced (eGFR at least 30) unless your creatinine is improving
  • Your liver enzymes are not more than 5 times normal (or you can be retested in 48 hours)
  • You are not pregnant, breastfeeding, or planning pregnancy

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07135778Recruiting
Combination antifungal therapy for fungal infections in blood cancer

This trial tests a combination of antifungal medicines (liposomal amphotericin B and either isavuconazole or posaconazole) for people with blood cancers who develop a fungal infection despite taking preventive antifungal drugs. It aims to find a better treatment for these difficult infections.

Tianjin, Tianjin Municipality
NCT07215273Recruiting· Phase 2
Testing a new antifungal for mold infections in immunocompromised people

This study tests a new antifungal drug (EL219) compared to two standard treatments (liposomal amphotericin B or voriconazole) for people with weakened immune systems who have a suspected or confirmed mold infection. The goal is to see if the new drug works as well or better at treating the infection.

Birmingham, Alabama
NCT06925321Recruiting· Phase 3
Testing Fosmanogepix for Serious Mold Infections

This trial tests a new drug, Fosmanogepix, for treating serious mold infections that are hard to treat with current medicines. It may be an option for people with limited treatment choices.

Birmingham, Alabama
NCT06819410Recruiting
Comparing antifungal treatments for invasive fungal disease

This trial studies two types of antifungal medicines (amphotericin B and azoles) to see which works better for people with invasive fungal disease. It aims to help doctors choose the safest and most effective treatment.

Chengdu, Sichuan
NCT06194201Recruiting· Phase 2
Study of HRS9432 for blood or organ yeast infection

This trial tests a new antifungal drug, HRS9432, for patients with candidemia (a yeast infection in the blood) or invasive candidiasis (yeast infection in organs). It aims to see if the drug is safe and works well for these serious infections.

Hengyang, Hunan
NCT02979951Recruiting
IV fosfomycin for serious bacterial infections

This trial studies whether IV (through a vein) fosfomycin can treat severe bacterial infections in adults. It may help people whose infection is covered by the standard fosfomycin use and who need hospital-level care.

Hall in Tirol

Hear when a new Invasive Fungal Infection trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.